Buparlisib is the only PI3K inhibitor that has (in combination with paclitaxel) resulted in a clinical benefit in R/M HNSCC in the phase 2 BERIL-1 trial (12). Here, PIK3CA is linked to head and neck squamous cell carcinoma.